The management sounded buoyant and expects market share gains across categories on the back of innovation-led product launches and enhanced…
With the appointment of Gill as the new MD & CEO, the key aspect to watch out would be his…
Oberoi Mall reported strong revenue/Ebitda of Rs 3.9 billion/3.7 billion in Q3 (up 40% y-o-y) led by strong rental escalations…
FY20/FY21e EPS cut 9/10%; ‘Buy’ maintained with TP revised to Rs 566 from Rs 620.
DevCo becoming FCF positive FY19 onwards to be a key trigger for rerating; ‘Buy’ retained.
IEX’ DAM volume grew 19% in 9M on higher demand by discoms (80% share).
NTPC/PGCIL upgraded to ‘Buy’ with revised TP of Rs 172/213, respectively; valuations are compelling
Vertical demerger a better option for execution of global deal with Hitachi; downgraded to ‘Hold’ on stock price run-up.
In near term, growth is expected on key approvals/launches in the US coupled with healthy growth in Natrol (expects double…
Company will continue expanding capacity at low capex with quality assets and low cost of production; ‘Buy’ retained
To revive growth, company has initiated measures like higher media spends, product launches at lower price points and enhanced focus…
Volumes expected to recover in FY20; HMCL can rerate due to medium-term volume uptick; ‘Buy’ maintained
REC’s core business remains strong with improving asset quality and revival in loan growth.
It’s expected to post FY19 revenue/PAT of Rs 74/3.2 bn; target price pegged at Rs 157
Fall in copra price to drive healthy Ebitda growth in H2FY19; EPS raised by 2-3% for FY20-21e; TP up to…
EBITDA at `21 bn, up 53% YoY, exceeded our/consensus estimate of `19 bn mainly due to (1) better-than-expected profitability of…
While we expect China and global injectable business to scale up in two-three years, US sales would improve with new…
One of best plays on building material industry with bright prospects; ‘Buy’ maintained.
